Showing results (391-400 of 400) with videos related to
Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 400 results.
JAMA Neurology|March 4, 2024
Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical TrialChong Yan, Yaoxian Yue, Yuzhou Guan, et al.Mabs|August 4, 2020
Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activityRaul C Camacho, Seohee You, Katharine E D'Aquino, et al.Cancer Letters|September 5, 2021
CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphomaYichen Sun, Yan Gao, Jianfeng Chen, et al.American Journal of Hematology|August 30, 2023
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label studyLijuan Deng, Zhiming Li, Huilai Zhang, et al.The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.Journal of Hematology & Oncology|March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Bo Jia, Wei Xu, et al.The Lancet. Oncology|December 28, 2019
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populationsGuo-Wang Lin, Caigang Xu, Kexin Chen, et al.American Journal of Hematology|June 21, 2022
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohortJing Quan Lim, Dachuan Huang, Jason Yongsheng Chan, et al.Pageof 40